Pay in 4 interest-free payments of $6.35 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
2024;16(11):e73415
100% of patients in the REVEAL-1 Cohort maintained at least 5% of GLP-1-induced weight loss through one year: This 5% threshold is the responder definition used as the second co-primary endpoint in the REMAIN-1 Pivotal Cohort, which evaluates a responder rate among the Revita treated participants at one year to assess the durability of the Revita procedure for weight maintenance after GLP-1 discontinuation
Topical penetration beyond the epidermis in intact skin remains the major unresolved limiting factor
Commonly reported issues include: Digestive discomfort: Some may experience minor bloating or cramping
Structured follow-ups
If youve been taking a GLP-1 medication consistently and arent seeing the results you expected, its worth discussing alternative treatment options with a bariatric specialist
US$ 22.13
US$ 20.57
US$ 25.79
US$ 23.80
US$ 29.63
US$ 24.07
